Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9737415 | 1.00 | PGD (0.32) | PGDCA4 | |
| SCHEMBL9737419 | 1.00 | PGD (0.32) | PGDCA4 | |
| SCHEMBL17671289 | 1.00 | PGD (0.32) | PGDCA4 | |
| SCHEMBL9738853 | 1.00 | PGD (0.32) | PGDCA4 | |
| SCHEMBL1533864 | 1.00 | PGD (0.32) | PGDCA4 | |
| SCHEMBL9736791 | 1.00 | PGD (0.32) | PGDCA4 | |
| SCHEMBL9738142 | 1.00 | PGD (0.32) | PGDCA4 | |
| SCHEMBL6544113 | 1.00 | PGD (0.32) | PGDCA4 | |
| SCHEMBL9737343 | 1.00 | PGD (0.32) | PGDCA4 | |
| SCHEMBL9738406 | 1.00 | PGD (0.32) | PGDCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 217 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240076704-A1 | PRODUCTION OF BIOPRODUCT IN A HOST CELL | INBIOSE N.V. (BE) | 2024-03-07 | — | — | US | claimed |
| EP-2905621-B1 | MEANS AND METHODS FOR DIAGNOSING AND TREATING CDG CAUSED BY A DEFICIENCY OF PGM1 | UNIV MUENSTER WESTFAELISCHE WILHELMS (DE) | 2018-05-02 | — | — | EP | claimed |
| EP-2905621-A1 | Means and methods for diagnosing and treating CDG caused by a deficiency of PGM1 | Westfälische Wilhelms-Universität Münster (DE) | 2015-08-12 | — | — | EP | claimed |
| EP-1032709-B1 | METHOD AND APPARATUS FOR PRESERVING HUMAN SALIVA FOR TESTING | SCHNEIDER DAVID R (US) | 2008-06-11 | — | — | EP | claimed |
| EP-1032709-A4 | METHOD AND APPARATUS FOR PRESERVING HUMAN SALIVA FOR TESTING | SCHNEIDER DAVID R (US) | 2007-01-10 | — | — | EP | claimed |
| US-7094582-B2 | Cell-free production of glucosamine | ARCHER-DANIELS-MIDLAND COMPANY (US) | 2006-08-22 | — | — | US | claimed |
| EP-1546352-A2 | CELL-FREE PRODUCTION OF GLUCOSAMINE | Archer-Daniels-Midland Company (US) | 2005-06-29 | — | — | EP | claimed |
| US-20050042734-A1 | Cell-free production of glucosamine | ARCHER-DANIELS-MIDLAND COMPANY | 2005-02-24 | — | — | US | claimed |
| EP-1292312-B1 | DIETARY SUPPLEMENT ENHANCING THE MUSCULAR ENERGY METABOLISM, COMPRISING AN ALKANOYL CARNITINE AND RIBOSE | SIGMA TAU IND FARMACEUTI (IT) | 2004-04-28 | — | — | EP | claimed |
| WO-2004031396-A2 | CELL-FREE PRODUCTION OF GLUCOSAMINE | ARCHER-DANIELS-MIDLAND COMPANY (US) | 2004-04-15 | — | — | WO | claimed |
| US-6291178-B1 | A KIT CONTAINING AN IONIC SOLUTE THAT WHEN DILUTED CREATES A SOLUTION WITH AN ISOMOLALITY OF NORMAL PHYSIOLOGICAL BODY FLIUD AND AN ENZYMATIC INHIBITOR; SALIVA SAMPLE IS COLLECTED INTO A SPECIMEN CUP AND SEALED THAT IS TAMPERED RESISTANT | SCHNEIDER DAVID R (US) | 2001-09-18 | — | — | US | claimed |
| EP-1032709-A1 | METHOD AND APPARATUS FOR PRESERVING HUMAN SALIVA FOR TESTING | Schneider, David R. (US) | 2000-09-06 | — | — | EP | claimed |
| US-5968746-A | KIT FOR DIRECT COLLECTION AND PRESERVATION OF SALIVA SAMPLE; INCLUDES IONIC SOLUTE WHICH WHEN DILUTED HAS OSMALITY OF PHYSIOLOGICAL FLUID AND ENZYME INHIBITOR TO PREVENT BREAKDOWN OF HYDROPHILIC COMPOUND TO BE TESTED; DRUG ABUSE | SCHNEIDER DAVID R (US) | 1999-10-19 | — | — | US | claimed |
| WO-1999027139-A1 | METHOD AND APPARATUS FOR PRESERVING HUMAN SALIVA FOR TESTING | SCHNEIDER DAVID R (US) | 1999-06-03 | — | — | WO | claimed |
| EP-0005867-B2 | AN ALPHA-AMYLASE ASSAY, A REAGENT COMPOSITION AND A REAGENT SYSTEM THEREFOR | COOPERBIOMEDICAL, INC. (US) | 1986-07-09 | — | — | EP | claimed |
| EP-0147867-A2 | Method for the enzymatic determination of inorganic phosphate, and its application | de Groot, Herbert, Dr. (DE) | 1985-07-10 | — | — | EP | claimed |
| EP-0005867-B1 | AN ALPHA-AMYLASE ASSAY, A REAGENT COMPOSITION AND A REAGENT SYSTEM THEREFOR | COOPERBIOMEDICAL, INC. (US) | 1982-10-27 | — | — | EP | claimed |
| US-20260139285-A1 | SACCHARIDE IMPORTERS FOR LACTO-N-TRIOSE | INBIOSE N V (BE) | 2026-05-21 | — | — | US | disclosed |
| US-4654323-A | BLOCKING AGENT FOR CALCIUM CALMODULIN COMPLEX | BAR ILAN UNIVERSITY (IL) | 1987-03-31 | — | — | US | disclosed |
| EP-0168626-A1 | Composition for the manufacture of a medicament for the therapeutic treatment of trauma of the skin | BAR-ILAN UNIVERSITY (IL) | 1986-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260139285-A1 | SACCHARIDE IMPORTERS FOR LACTO-N-TRIOSE | GALNT3, NANS, ENGASE | PGD 69/4885CA4 790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.